Hi [[ session.user.profile.firstName ]]

pharmaphorum

  • Date
  • Rating
  • Views
  • Pharma’s digital landscape: the evolution of multichannel strategy
    Pharma’s digital landscape: the evolution of multichannel strategy Paul Tunnah (Moderator) with Oksana Matviienko (Viseven), Bogdan Rakytskyi (Teva) and Chris Wade (Veeva Systems) Recorded: Sep 19 2017 72 mins
    Pharmaceutical marketers are increasingly native multichannel practitioners, but building an effective and efficient campaign is challenging.
    This is also because the digital landscape, and the number of options available is still rapidly evolving.
    What are the best ways to choose the right channels and the right content? And how can you plan to optimize operations further by cutting down on costs and approval times?
    This webinar brings together experts in digital marketing with case studies from a leading pharmaceutical company to keep you up to date with the latest technology and trends and provide practical advice on how to maximize your impact.
    Within one hour, you’ll discover how to optimize and streamline all content-related processes within a single platform: starting with concept development and ending with the final launch. What is more, you will find out how to reuse and repurpose your ready-made content cost-effectively, as well as save time while adapting and updating content through its whole lifecycle.
    Focus
    •How to develop best practice and a winning multichannel strategy
    •Making sure your content supports face-to-face interactions
    •Transforming the commercial teams to deliver successful digital and multichannel projects
    •How to innovate in multichannel, and the potential of future integration solutions
  • Pharma and proactive, preventative healthcare: how to use the pharmacy channel
    Pharma and proactive, preventative healthcare: how to use the pharmacy channel Andrew McConaghie (moderator), John Munson, Nemanja Jankovic and Nina Felton Recorded: Sep 6 2017 70 mins
    Across Europe, a shift towards greater prevention, earlier diagnosis and treatment is needed in order to contain the growing cost of healthcare.
    But how can healthcare systems make this transition – and how do pharmaceutical companies play a role in this, while also growing their market?
    A forthcoming webinar hosted by pharmaphorum with sponsor PHOENIX group looks at how harnessing the data and expertise of pharmacies, and via greater engagement with patients, consumers and shoppers can meet this emerging need.
    •Industry: how can pharma switch from treating a disease to earlier health management?
    The role of preventative medicine, vaccines and early diagnosis explored
    •The role of community pharmacies in prevention and health – increasing screening and diagnosis rates and facilitating appropriate medication
    •How point of sale information in pharmacies can help generate a picture of patient groups and individuals. How loyalty card schemes support OTC and consumer spending patterns, which illuminate health needs, prescription patterns and purchasing behaviour
  • How to maximise the value of digital in medtech
    How to maximise the value of digital in medtech Paul Tunnah, pharmaphorum Recorded: Jun 29 2017 64 mins
    With a wealth of market and regulatory changes impacting the medtech sector, it’s time for digital technology to steer the direction of your future business. This expert webinar will evaluate how to strategically embed digital within your own organisation and explore the challenges and the opportunities for transforming customer relationships, driving commercial outcomes.

    – Respond to the changing regulatory environment: how technology empowers your business
    – Build a business case for digital transformation and gain organisational support
    – Strengthen your customer relationships and improve engagement in a diverse payer landscape
    – Learn from pharma (and other industries) to find opportunities and avoid pitfalls
    – Measure impact and return on investment from digital engagement
  • Disruption and maturity: the future directions for biologics in healthcare
    Disruption and maturity: the future directions for biologics in healthcare Paul Tunnah (moderator), Angela McFarlane, Sarah Rickwood, Margaret Dolan and Timothy C. de Gavre Recorded: Jun 20 2017 65 mins
    A digital debate analysing the future for biologics in the UK and the factor affecting market access in this territory. Our expert panel will cover a number of key topics including:

    •Are the savings offered by biosimilars being used to innovate and take advantage of the exciting new biologic technologies or just filling in the NHS potholes?
    •Will the industry continue to invest in cutting-edge research if the UK is not prepared to fund access to it
    •In a post-Brexit world how can the UK continue to be a global leader at the cutting edge of biologics research?
  • Powering pharma’s commercial teams with market access insights
    Powering pharma’s commercial teams with market access insights Paul Tunnah, Leilani Latimer and John Stahl Recorded: Jun 12 2017 63 mins
    Market access is influencing drug development and commercial launch strategy more than ever before, with 85% of prescription drugs in the United States reimbursed through managed care plans. Biopharma companies must take into account a multitude of factors when considering physician prescribing behaviors, and need a more integrated "pull-through" strategy across their teams, from managed markets, to marketing, to field sales. Just as an engine needs a steady supply of fuel to run efficiently, prescriber-facing teams – the commercial engine of life sciences companies – need market access data and insights to accelerate brand success. Today, the challenge is optimizing this fuel supply, as market access and commercial teams often operate in a siloed way with regards to data, market changes and insights.
    Join a vibrant conversation with industry leaders to discuss how the industry is changing and adapting to operationalize market access pull-through for improved commercial success.
  • The future of the clinical trial – collaboration and patient centricity
    The future of the clinical trial – collaboration and patient centricity Jameisha Brown, Eric Delente, Paulo Moreira, Christine Phillips, Andrew McConaghie Recorded: May 3 2017 73 mins
    Growing patient influence combined with new technologies and the requirements of new reimbursement models means clinical research is undergoing rapid transformation. Industry is being compelled to move towards more patient centric solutions to keep up with these changes. With healthcare stakeholders in agreement that patient engagement is key to realising the value of clinical trials, regulators, sponsors, CROs, research funders and publishers are all moving towards more patient-focused models.

    With the advent of new methodologies, such as electronic data sources and medical records, recruiting patients for trials now demands extensive collaboration between patients and trial centers to effectively and efficiently run trials. The patient has never been more important.

    To mark Clinical Trials Awareness Week, pharmaphorum, in partnership with INC, will present a live webinar exploring the challenges and solutions of the current environment and how collaboration can benefit research participation, as well as the vital role the patient advocate plays in these matters.
  • Life sciences promotional content management for speed, compliance and insight
    Life sciences promotional content management for speed, compliance and insight David Bennett, Andrew McConaghie Recorded: Apr 27 2017 69 mins
    The life sciences landscape is moving at a rapid pace, which in turn is increasing the demands on marketers to create innovative, digital content faster while maintaining industry compliance.

    Veeva Systems recently conducted an annual industry study, focused on content and digital asset management within life sciences. Gleaned from the experiences and opinions of leaders across the life sciences industry, the research uncovers current practices and the industry’s need for more advanced approaches for global marketing and regulatory compliance.

    Join this webinar to hear the key insights from the survey results, and discuss key highlights with host David Bennett, VP Commercial Content Strategy Europe, Veeva.

    From this webinar you will:

    – Learn the current state of commercial content and digital asset management in life sciences promotions
    – Garner an understanding of how your organization compares to the industry
    – Understand how to accelerate your content across the digital supply chain
  • When small becomes big: orphan medicines, advances, access and affordability
    When small becomes big: orphan medicines, advances, access and affordability Alastair Kent OBE, Malcolm Qualie, Sheela Upadhyaya, Sarah Rickwood, Moderated by Paul Tunnah Recorded: Apr 10 2017 75 mins
    Over the past few years there has been a shift in the European pharmaceutical market landscape, with a rise in specialty medicines for diseases with narrow patient populations. Indeed, QuintilesIMS forecasts that, between 2013 and 2018, 94% of list price value growth will be in specialty medicines – with orphan drugs at the forefront of this trend.
    On 10 April 2017, QuintilesIMS, in partnership with pharmaphorum presents a unique digital debate, bringing together a panel of senior industry experts, including participants from NICE, NHS England and Genetic Alliance UK to explore the pillars of commercial success for orphan drugs in Europe in the context of changes in reimbursement processes and broader future challenges, like Brexit.
  • Unlocking the value of pharmacists to reach the right patients and consumers
    Unlocking the value of pharmacists to reach the right patients and consumers Pierre-Yves Boisvert, Paulien Schul, Nina Felton and Andrew McConaghie Recorded: Mar 29 2017 70 mins
    Pharmacists are highly trained healthcare professionals who have a deep understanding of medicines and daily contact with patients and consumers. This puts them in a unique position in terms of being able to maximise the benefits that patients get from their medicines – however, healthcare systems and pharmaceutical companies frequently overlook this potential.
    Pharmacists are especially well placed to help patients with multiple long-term conditions manage their health and medications, and pharmacist-led interventions have been shown to have a very significant impact on compliance and disease management in the community.
    We present a webinar debate in which our expert panel will discuss how pharmaceutical companies can work in collaboration with pharmacists in Europe to help patients make the most of their medicines, help generate data to prove the value of these interventions, and above all get the right medicine to the right patients and consumers.
    Join us and the PHOENIX group as we look at the practical steps needed to make this a reality. Key topics to be discussed include:
    •The challenges of identifying the right patient population across European markets
    •Understanding how pharmacists can play a greater role in patient care, e.g. improved adherence and outcomes
    •How optimum use of pharmacy level information can contribute to providing ‘real world’ evidence of treatments
  • Approval and access: Overcoming the final hurdle of drug development
    Approval and access: Overcoming the final hurdle of drug development Professor Luca Pani, University of Miami, Angelika Joos,MSD (Europe) Inc. Ana Palma, Sobi, Belgium Recorded: Mar 10 2017 61 mins
    2017 is once again a year of significant change for pharma market access in Europe, with affordability on the agenda for almost every country in the region. There is a move toward greater collaboration in health technology assessment and more transparency between countries for pricing, therapeutic protocols and and details of negotiations with drug manufacturers. We also see member states working to understand the process of enabling cost-effective patient access to personalised and high-cost treatments, such as new oncology combination therapies, antibiotics and stem cell therapies, which offer the promise of efficacy in key disease areas.

    With market access being referred to as the “fourth hurdle” in drug development (beyond efficacy, safety and quality), it is vital that the requirements for both approval and access are addressed early in the process. Parallel scientific advice from HTA bodies and regulators is increasing to deliver tangible and successful strategies, but is the process smooth enough to overcome the challenges from both sides?

    pharmaphorum in partnership with DIA will be hosting an expert panel debating the best way forward for life sciences companies, payers and providers in this emerging European market access paradigm.

    Join our webinar to hear from experts in industry and healthcare discussing the challenges and solutions of access in the changing European market.
    Topics up for discussion include:
    •Integrating HTA and regulatory strategy – the best way forward
    •Regional variation and implication – how to efficiently and effectively navigate EU market access
    •Proving value – how to leverage real world evidence to meet increasing demands for observational data
    •Future proofing market access – how to improve upon evidence generation and use technology effectively and competitively

Embed in website or blog